ATHE and ATH.AX Related Headlines
Go Back- Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA
- Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
- Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
- Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
- Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
- Alterity Therapeutics receives FDA alignment on ATH434 manufacturing plans
- Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
ATHE and ATH.AX Related Press Releases
Go Back- Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
- Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
- Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
- Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
- Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
